- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ProKidney forciert Spätphasenprogramm für Nierenzelltherapie: Entscheidende Meilensteine für 2027 avisiert | 1 | Investing.com Deutsch | ||
| Mo | PROKIDNEY CORP. - 8-K, Current Report | - | SEC Filings | ||
| 29.10. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.10. | ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update | 1 | GlobeNewswire (USA) | ||
| 02.10. | ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026 | 1 | GlobeNewswire (USA) | ||
| 10.08. | ProKidney GAAP EPS of -$0.15 misses by $0.01, revenue of $0.15M in-line | 1 | Seeking Alpha | ||
| 10.08. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 10.08. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.06. | Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel's Accelerated Approval Path | 1 | Insider Monkey | ||
| 02.06. | ProKidney beruft Kenneth Locke zum Chief Technical Officer | 2 | Investing.com Deutsch | ||
| 02.06. | ProKidney Appoints Kenneth Locke as Chief Technical Officer | 287 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| 18.05. | ProKidney GAAP EPS of -$0.14 beats by $0.01, revenue of $0.23M beats by $0.03M | 1 | Seeking Alpha | ||
| 15.05. | ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates | 1 | Zacks | ||
| 15.05. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 8 | SEC Filings | ||
| 15.05. | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | 508 | GlobeNewswire (Europe) | On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase... ► Artikel lesen | |
| 25.03. | ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer | 402 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVOSIM LABS | 0,129 | 0,00 % | VivoSim Labs, Inc.: VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting | ||
| INOVIO PHARMACEUTICALS | 1,161 | -10,35 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| ARGENX | 869,60 | -0,07 % | JPMORGAN stuft Argenx auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Argenx mit einem Kursziel von 950 Euro auf "Overweight" belassen. Die Übernahme des bisherigen Forschungspartners Unnatural... ► Artikel lesen | |
| NORTHWEST BIOTHERAPEUTICS | 0,140 | 0,00 % | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Expansion of Its Technical Team | Northwest Biotherapeutics Announces Expansion of Its Technical Team
Company Expanding Key Operational AreasBETHESDA, Md., Oct. 26, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) NWBio... ► Artikel lesen | |
| EQUILLIUM | 1,245 | -5,68 % | Equillium, Inc.: Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 | On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,510 | 0,00 % | Enveric Biosciences Reports Favorable Brain Activity Data for Lead Psychiatric Drug Candidate | ||
| REGENCELL BIOSCIENCE | 5,220 | -0,19 % | Holzer & Holzer LLC: RGC INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the June 23, 2026 Lead Plaintiff Deadline in the Regencell Bioscience Holdings Limited Securities Class Action | Atlanta, Georgia--(Newsfile Corp. - June 16, 2026) - A shareholder class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC).... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 12,440 | -0,16 % | 4D Molecular Therapeutics, Inc.: 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME | 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 2,950 | -8,67 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts | - Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global... ► Artikel lesen | |
| RELMADA THERAPEUTICS | 3,760 | -1,57 % | Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer | Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES... ► Artikel lesen | |
| BIOATLA | 1,800 | +3,75 % | Context Therapeutics Inc.: Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 1,350 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up | Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors
In the 14 efficacy-evaluable patients:
71.4% stable disease... ► Artikel lesen | |
| BOUNDLESS BIO | 2,450 | 0,00 % | Boundless Bio, Inc. - 10-Q, Quarterly Report | ||
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| VOR BIOPHARMA | 19,550 | -0,05 % | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
PROKIDNEY CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,120 Euro und damit +0,90 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.